Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 7/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21953750 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL18665275 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL22430757 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL25004569 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL20887283 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24344812 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL21242959 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL25067444 | 0.99 | MAPT (0.41) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL22646039 | 0.98 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL26319068 | 0.92 | PRKCA (0.38) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096626-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20190351040-A1 | RNA CANCER VACCINES | MODERNATX, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190022019-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10172808-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096626-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | NSUN2, NSUN3, RNMT | MAPT 874/4885MAPK1 3877/4885PRKCA 1038/4885 |
| US-10172808-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | MAPT 4546/4885MAPK1 2097/4885PRKCA 1042/4885 |
| US-20190351040-A1 | RNA CANCER VACCINES | TP53, KRAS, STING1 | MAPT 4139/4885MAPK1 1867/4885PRKCA 206/4885 |
| US-20190022019-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | POLM, EMG1, MCM6 | MAPT 3723/4885MAPK1 4072/4885PRKCA 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.